Menu UF Health Home Menu

Kirk P. Conrad, M.D.


Kirk P. Conrad, M.D.

Kirk P. Conrad, M.D.

(352) 392-2798

Office: MSB MG-40A

PubMed Listing


Co-Organizer of the Reproductive and Perinatal Biology Research Program (

Research Interests

A long-standing research interest is to understand the mechanisms underlying the massive systemic maternal vasodilation and increased arterial compliance that transpire during normal pregnancy. Another is the dysregulation of these maternal circulatory adaptations in preeclampsia (a hypertensive disease of pregnancy), and the potential etiological role of aberrant endometrial maturation in the defective placentation associated with preeclampsia and other placental syndromes such as intrauterine growth restriction. Ultimately the goal is to apply the new knowledge gained from these investigations towards the development of mechanistic-based preventative, therapeutic and curative measures for these obstetrical diseases. We found that the ovarian hormone relaxin is a potent vasodilator in the systemic and renal circulations, and that it contributes to the remarkable changes in the vasculature during pregnancy. These discoveries provided the scientific basis and motivation for pursuing the hormone as a therapy for afterload reduction in heart failure. We unveiled endothelial mechanisms of systemic vasodilation in pregnancy, and here our independent investigations of the cardiovascular effects of pregnancy and relaxin converged, leading to the elucidation of endothelial mechanisms for both “rapid” and “sustained” vasodilation by relaxin. We also observed that, unexpectedly, relaxin was equally potent in the vasculature of males, and to explain this finding we hypothesized the existence of local relaxin ligand-receptor expression and function in arteries, for which we subsequently provided both molecular and functional evidence. More recently, we found a new role for relaxin in bone marrow angiogenic progenitor cell mobilization and function, and in the context of pregnancy. A final aim has been to apply the “lessons learned from pregnancy” to further understand and treat cardiovascular disease in the non-pregnant population (e.g., heart failure). It should be noted that we always strive to translate discoveries made in preclinical investigations to humans. As one example, we are currently investigating the cardiovascular adaptations and obstetrical outcomes of pregnancies in women conceiving by Assisted Reproductive Technologies (ART) (in comparison to spontaneously conceived pregnancies), because ART occurs in the setting of nil or as many as 20 corpora lutea, thus dramatically effecting the circulating levels of relaxin and other potentially vasoactive corpus luteal hormones. As another example, we recently investigated global gene expression in chorionic villus samples from women who later developed preeclampsia. After secondary analyses of the 168 genes altered in the CVS from women who developed preeclampsia, we find that as many as 45 genes are associated with decidualization or in this case, inadequate decidualization. Dr. Conrad and colleagues at the University of Florida are well situated to take these exciting findings to the next level. A long-term goal is to understand the etiology of preeclampsia, which will facilitate discovery of biomarkers for disease prediction, and strategies for prophylaxis and therapy. We believe that it is especially important to integrate Reproductive and Perinatal Medicine, in order to unveil etiology and develop preventative therapies for adverse pregnancy and neonatal outcomes.

Recent Publications:

Jelinic M., Leo C.H., Post Uiterweer E.D., Sandow S.L., Gooi J.H., Wlodek M.E., Conrad K.P., Parkington H., Tare M., and Parry L.J. Localization of relaxin receptors in arteries and veins, and region-speific increases in compliance and bradykinin-mediated relaxation after in vivo relaxin treatment. FASEB J. 28:275-87, 2014.

Conrad KP and Davison JM. The renal circulation in normal pregnancy and preeclampsia. Is there a place for relaxin? Am J Physiol. Renal Fluid and Electrolyte Physiol., 2014 May 15, 306:F1121-35. (Invited Review). [Link to full paper]

Conrad K.P. and Karumanchi S.A. Renal Physiology and Disease in Pregnancy. In: Seldin and Giebisch’s The Kidney. Physiology and Pathophysiology: Fifth Edition. R.J. Alpern, M.J. Caplan, O.W. Moe eds. Academic Press, San Diego. 2689-2761, 2013.

Conrad K.P. and Baker V.L. Corpus luteal contribution to maternal pregnancy physiology and outcomes in assisted reproductive technologies. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 304:R69-72, 2013 (Perspectives).

Conrad K.P., Gaber L.W., and Lindheimer M.D. The Kidney in Normal Pregnancy and Preeclampsia. In: Chesley’s Hypertensive Disorders in Pregnancy: Fourth Edition. Robert N. Taylor, James M. Roberts, F. Gary Cunningham, and Marshall D. Lindheimer (eds.). Elsevier. In press.

Segal M.S., Sautina L., Li S., Diao Y., Agoulnik A.I., Kielczewski J, McGuane J.T., Grant M.B., and Conrad K.P. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 119:629-36, 2012.

McGuane J.T. and Conrad K.P. GPCRs as potential therapeutic targets in preeclampsia. Drug Discover Today: Disease Models. 9(3):e119-e127, 2012 (invited review).

Vodstrcil L.A., Tare M., Novak J., Dragomir N., Ramirez R.J., Wlodek M.E., Conrad K.P., and Parry L.J. Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow. FASEB J. 26:4035-44, 2012.

Yu May Soh, Anjana Tiwari, Mala Mahendroo, Kirk P Conrad and Laura J Parry. Relaxin regulates hyaluronan synthesis and aquaporins in the cervix of late pregnant mice. Endocrinol. 153:6054-64, 2012.

Founds S. A., Terhorst L. A., Conrad K.P., Hogge W. A., Jeyabalan A. and Conley Y. P. Gene expression of eight candidates in first trimester preeclampsia placenta. Biological Research for Nursing 13:134-139, 2011.

McGuane J.T., Debrah J.E., Sautina L., Rubin J.P., Novak J., Segal M.S. and Conrad K.P.  Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.  Endocrinol. 152:2786-96, 2011.

McGuane J.T., Danielson L.A., Debrah J.E., Rubin J.P., Novak J. and Conrad K.P.  Angiogenic growth factors are new players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57:1151-60, 2011.

Conrad K.P. Emerging role of relaxin in the maternal adaptations to normal pregnancy: Implications for preeclampsia.  Seminars Nephrol. 31: 15-32, 2011 (invited review).

Conrad K.P.  2010 Ernest H. Starling Lectureship. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol. Regulatory Integrative Comp. Physiol. 301:R267-275, 2011 (invited review).

Debrah D.O., Debrah J.E., Haney J.L., McGuane J.T., Sacks M.S., Conrad K.P. and Shroff S.G. Relaxin regulates vascular wall mechanical properties and remodeling in mice. J Appl Physiol. 111:260-71, 2011.

Conrad K.P. and Shroff S.G. Effects of relaxin on arterial tone and remodeling. Mediators Mechanisms, and Pathways in Tissue Injury section of Current Hypertension Reports (Volume 13, Issue 6). Taegtmeyer and Atlas, eds., 2011 (invited review).

Conrad K.P. Unveiling the vasodilatory actions and mechanisms of relaxin.  Hypertension 56:2-9, 2010 (invited review).

Jeyabalan A., and Conrad K.P. Renal Physiology and Pathophysiology in Pregnancy. In: Renal and Electrolyte Disorders. 7th edition. RW Schrier, ed. Lippincott Williams & Wilkins, Chapter 13, p. 462-518, 2010.

Conrad K.P. and Karumanchi S.A. Renal Physiology and Disease in Pregnancy. In: Seldin and Giebisch’s The Kidney. Physiology and Pathophysiology: Fifth Edition. Robert J. Alpern and Steven C. Hebert, editors, in press.

Recent Honors

2013 – University of Florida College of Medicine: Exemplary Teacher Award

2012 – Dutch Heart Foundation Lecturer

2010 – Ernest H. Starling Distinguished Lectureship of the American Physiological Society Water & Electrolyte Homeostasis Section

2010 – Liley Lecturer Perinatal Reseach Society

2010 – Senior Faculty Research Award University of Florida Chapter Sigma XI